METHODS: A 90-year-old female patient taking sacubitril/valsartan was admitted due to chronic heart failure. Subsequently, the patient developed serious liver injury with increased hepatic transaminases.
METHODS: Drug-induced liver injury, sacubitril/valsartan-related. No liver injury caused by other reasons was observed after thorough examination. After the withdrawal of sacubitril/valsartan, the liver function of the patient gradually returned to normal.
METHODS: We chose general liver protection methods to improve her hepatic function, including magnesium isoglycyrrhizinate at 100 mg daily and polyene phosphatidylcholine capsules at 456 mg 3 times daily. We consulted with a hepatologist to discuss the best plan for her treatment. The last, we stopped sacubitril/valsartan.
RESULTS: After the withdrawal of sacubitril/valsartan, the liver function of the patient gradually returned to normal.
CONCLUSIONS: Sacubitril/valsartan-induced liver injury is very rare. Clinicians should pay particular attention to the possibility of hepatotoxicity during sacubitril/valsartan treatment.
方法:一名服用沙库巴曲/缬沙坦的90岁女性患者因慢性心力衰竭入院。随后,患者出现严重的肝损伤,肝转氨酶升高。
方法:药物性肝损伤,沙库必曲/缬沙坦相关。彻底检查后未观察到其他原因引起的肝损伤。沙库必曲/缬沙坦停药后,患者肝功能逐渐恢复正常。
方法:我们选择了一般的肝脏保护方法来改善她的肝功能,包括异甘草酸镁每天100毫克和多烯磷脂酰胆碱胶囊456毫克每天3次。我们咨询了一位肝病专家,讨论了她治疗的最佳方案。最后,我们停止了沙库巴曲/缬沙坦。
结果:沙库巴曲/缬沙坦停药后,患者肝功能逐渐恢复正常。
结论:沙巴曲/缬沙坦诱导的肝损伤非常罕见。临床医生应特别注意沙库巴曲/缬沙坦治疗期间肝毒性的可能性。